Predictors of unsuccessful mobilization with granulocyte colony-stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation

Journal of Clinical Apheresis

Volumn 28, Issue 4, 2013, Pages 285-292

  Chow, Signy ^a   Lazo Langner, Alejandro ^a   Ormond, George ^a   Howson Jan, Kang ^a   Xenocostas, Anargyros ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

autologous transplantation; G CSF; hematopoietic stem cell transplant; mobilization

Indexed keywords

CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; COHORT ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; GROUPS BY AGE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SEX; STEM CELL MOBILIZATION;

AUTOLOGOUS TRANSPLANTATION; G-CSF; HEMATOPOIETIC STEM CELL TRANSPLANT; MOBILIZATION;

ADULT; AGED; ANTIGENS, CD34; COHORT STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 84882280333     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21252     Document Type: Article

References (32)

1. Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR, Chin-Yee IH,. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967-972.
2. Cashen AF, Lazarus HM, Devine SM,. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant 2007; 39: 577-588.
3. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W,. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
4. Jillella AP, Ustun C,. What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? Stem Cells Dev 2004; 13: 598-606.
5. Bender JG, To LB, Williams S, Schwartzberg LS,. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329-341.
6. Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A, Van Besien K, Dipersio J,. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009; 50: 1412-1421.
7. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B,. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
8. Sugrue MW, Williams K, Pollock BH, Khan S, Peracha S, Wingard JR, Moreb JS,. Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000; 39: 509-519.
9. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF,. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-1056.
10. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, O'Connor C, Berkman E, Erban JK, Sprague KA, Miller KB, Schenkein DP,. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059-2064.
11. Nakasone H, Kanda Y, Ueda T, Matsumoto K, Shimizu N, Minami J, Sakai R, Hagihara M, Yokota A, Oshima K, Tsukada Y, Tachibana T, Nakaseko C, Fujisawa S, Yano S, Fujita H, Takahashi S, Kanamori H, Okamoto S,; Kanto Study Group of Cell Therapy. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma. Am J Hematol 2009; 84: 809-814.
12. De Clercq E,. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003; 2: 581-587.
13. De Clercq E,. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009; 77: 1655-1664.
14. Hatse S, Princen K, Bridger G, De Clercq E, Schols D,. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002; 527: 255-262.
15. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G,. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-1874.
16. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G,; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
17. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf S, Horwitz M, Cooper D, Bridger G, Calandra G,; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
18. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR,. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 1373-1379.
19. Fruehauf S, Seggewiss R,. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected]. Br J Haematol 2003; 122: 360-375.
20. Nervi B, Link DC, DiPersio JF,. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006; 99: 690-705.
21. Pelus LM,. Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand. Curr Opin Hematol 2008; 15: 285-292.
22. DiPersio JF,. Can every patient be mobilized? Best Pract Res Clin Haematol 2010; 23: 519-523.
23. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U,. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009; 84: 335-337.
24. Canales MA, Fernandez-Jimenez MC, Martin A, Arrieta R, Caballero MD, Díez J, Quevedo E, García-Bustos J, San Miguel JF, Hernández-Navarro F,. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 2001; 86: 494-498.
25. Perea G, Sureda A, Martino R, Altés A, Martínez C, Cabezudo E, Amill B, Martín-Henao GA, González Y, Muñoz L, Peyret M, Brunet S, Sierra J,. Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 2001; 80: 592-597.
26. Boeve S, Strupeck J, Creech S, Stiff PJ,. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997-1003.
27. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W,. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
28. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, Grove B, Dye A, Bridger G,. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331-338.
29. Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G,. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009; 15: 249-256.
30. Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G, Calandra G,. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009; 15: 1578-1586.
31. Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ,., Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Litzow MR, Porrata LF, Winters JL, Kumar S. Cost effectiveness analysis of a risk-adapted algorithm for Plerixafor use in autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2013; 19: 87-93.
32. Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M,., MacPherson J, Winkler K, Silva M, Steinberg M, Matous J, Selvey S, Maris M, McSweenay PA,. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011; 17: 729-736.